"Antiviral Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
| Descriptor ID |
D000998
|
| MeSH Number(s) |
D27.505.954.122.388
|
| Concept/Terms |
Antiviral Agents- Antiviral Agents
- Agents, Antiviral
- Antivirals
- Antiviral Drugs
- Drugs, Antiviral
|
Below are MeSH descriptors whose meaning is more general than "Antiviral Agents".
Below are MeSH descriptors whose meaning is more specific than "Antiviral Agents".
This graph shows the total number of publications written about "Antiviral Agents" by people in this website by year, and whether "Antiviral Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 3 | 0 | 3 |
| 2008 | 5 | 1 | 6 |
| 2009 | 3 | 1 | 4 |
| 2010 | 4 | 4 | 8 |
| 2011 | 4 | 0 | 4 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 3 | 0 | 3 |
| 2015 | 6 | 5 | 11 |
| 2016 | 2 | 3 | 5 |
| 2017 | 3 | 4 | 7 |
| 2018 | 2 | 0 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 3 | 4 | 7 |
| 2021 | 2 | 3 | 5 |
| 2022 | 3 | 8 | 11 |
| 2023 | 1 | 2 | 3 |
| 2024 | 1 | 3 | 4 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antiviral Agents" by people in Profiles.
-
A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants. J Infect Dis. 2025 Mar 17; 231(3):e478-e487.
-
The dawn of preventing respiratory syncytial virus lower respiratory tract infections in children S Afr Med J. 2024 10 08; 114(10):e2582.
-
Safety and Pharmacokinetics of Nirsevimab in Immunocompromised Children. Pediatrics. 2024 Oct 01; 154(4).
-
Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY). Vaccine. 2024 Oct 24; 42(24):126276.
-
No Evidence for an Association of HIV and Antiviral Treatment With Changes in Framingham Cardiovascular Risk Score in the Ndlovu Cohort Study. J Am Heart Assoc. 2024 Jan 16; 13(2):e029637.
-
Navigating paediatric virology through the COVID-19 era (Review). Int J Mol Med. 2023 Sep; 52(3).
-
Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants. N Engl J Med. 2023 04 20; 388(16):1533-1534.
-
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Lancet Child Adolesc Health. 2023 03; 7(3):180-189.
-
Drug-drug interaction with oral antivirals for the early treatment of COVID-19. Int J Infect Dis. 2023 02; 127:171-172.
-
Molecular characterization and genotyping of hepatitis C virus from Sudanese end-stage renal disease patients on haemodialysis. BMC Infect Dis. 2022 Nov 14; 22(1):848.